Parametric Portfolio Associates’s Spyre Therapeutics SYRE Stock Holding History

Parametric Portfolio Associates’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$409K	Buy	7,121 +5,442	+324%	+$457K	﹤0.01%	3179
2021 Q4	$199K	Sell	1,679 -125	-7%	-$19.7K	﹤0.01%	3429
2021 Q3	$359K	Buy	1,804 +478	+36%	+$83.6K	﹤0.01%	3230
2021 Q2	$231K	Buy	1,326 +262	+25%	+$47.6K	﹤0.01%	3355
2021 Q1	$211K	Buy	1,064 +6	+0.6%	+$1.15K	﹤0.01%	3860
2020 Q4	$208K	Buy	1,058 +48	+5%	+$9.95K	﹤0.01%	3757
2020 Q3	$179K	Sell	1,010 -195	-16%	-$36.1K	﹤0.01%	3691
2020 Q2	$279K	Buy	+1,205	New	+$229K	﹤0.01%	3504
2019 Q2	–	Sell	-450	Closed	-$91K	–	4000
2019 Q1	$91K	Buy	+450	New	+$93.8K	﹤0.01%	3828

Other funds holding SYRE

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return